Further understanding of molecular mechanisms underlying the regulation of ASK1 activity will provide opportunities to identify novel therapeutic targets and to develop promising therapeutic compounds for treatment of NAFLD/NASH. The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatotic liver disease.